Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26922761 | 0.91 | KCNH2 (0.45) | DRD2SIGMAR1HSD17B10HTR1ADRD3 | |
| SCHEMBL4576516 | 0.84 | DRD2 (0.46) | DRD2SIGMAR1HSD17B10HTR1ADRD3 | |
| SCHEMBL4575709 | 0.81 | DRD2 (0.44) | DRD2SIGMAR1HTR1ADRD3HTR2A | |
| SCHEMBL8350747 | 0.81 | MAPT (0.58) | DRD2SIGMAR1HSD17B10HTR1AHTR2A | |
| SCHEMBL4576289 | 0.81 | DRD2 (0.68) | DRD2SIGMAR1HTR1ADRD3KCNH2 | |
| SCHEMBL24681554 | 0.80 | KDM4E (0.60) | DRD2SIGMAR1HTR1ADRD3HTR2A | |
| SCHEMBL1812286 | 0.80 | MAPT (0.62) | DRD2SIGMAR1HSD17B10HTR1ADRD3 | |
| SCHEMBL29964154 | 0.80 | DRD2 (0.51) | DRD2SIGMAR1HSD17B10HTR1ADRD3 | |
| SCHEMBL19099996 | 0.80 | DRD2 (0.73) | DRD2SIGMAR1HSD17B10HTR1AHTR2A | |
| SCHEMBL6151540 | 0.80 | MAPT (0.62) | DRD2SIGMAR1HSD17B10HTR1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-2017278-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-2376493-B1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD KK (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8791125-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8575179-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8507505-B2 | Dihydropyrazolopyrimidinone derivative | MSD K.K. (JP) | 2013-08-13 | — | — | US | disclosed |
| EP-2376493-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD K.K. (JP) | 2011-10-19 | — | — | EP | disclosed |
| EP-2376494-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | MSD K.K. (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20110243891-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD K.K. | 2011-10-06 | — | — | US | disclosed |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | ALTMANN EVA | 2006-04-06 | — | — | US | disclosed |
| WO-2005049028-A1 | USE OF CATHEPSIN K INHIBITORS IN SEVERE BONE LOSS DISEASES | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2005-03-10 | — | — | US | disclosed |
| WO-2005014006-A1 | COMBINATIONS OF A CATHEPSIN K INHIBITOR AND A BISPHOPHONATE IN THE TREATMENT OF BONE METASTASIS, TUMOR GROWTH AND TUMOR-INDUCED BONE LOSS | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| CN-1549817-A | Pyrrolo pyrimidines, process for their preparation, their use and pharmaceutical compositions containing them | ��˹��ŵ�� | 2004-11-24 | — | — | CN | disclosed |
| EP-1423121-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| EP-1423391-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | CTSK, CTSS, CTSZ | DRD2 4870/4885SIGMAR1 4770/4885HSD17B10 3939/4885 |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | DRD2 4763/4885SIGMAR1 4150/4885HSD17B10 3166/4885 |
| US-20110243891-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | WEE2, WEE1, RPS6KA1 | DRD2 2931/4885SIGMAR1 1974/4885HSD17B10 3210/4885 |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | DRD2 2713/4885SIGMAR1 724/4885HSD17B10 3046/4885 |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | DRD2 4752/4885SIGMAR1 4489/4885HSD17B10 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.